Aurinia Pharmaceuticals (NASDAQ:AUPH) announces the last patient visit in its Phase 3 clinical trial, AURORA, evaluating voclosporin in patients with lupus nephritis. Topline data should be available later this quarter.
On another note, it has completed the sale of
~2.4M common shares under its at-the-market sales agreement with
Jefferies at a weighted average price of $6.40. Gross proceeds were
~$15M.
https://seekingalpha.com/news/3506066-aurinia-advances-late-stage-voclosporin-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.